SEC Form 4 · accession 0001179110-18-001812
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Feb 8, 2018
Accepted (ET)
Feb 8, 2018 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2018 | A | 22,500 | $0.00 | A | 326,039 | D | |
| Common Stock | holding | — | — | — | 184,985 | I | By spouse trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $3.01 | Feb 8, 2018 | A | 45,000 | A | — | Feb 8, 2028 | Common stock | 45,000 | 45,000 | D |
Explanation of responses
- F1Represents restricted stock units that will vest 1/4 annually over a 4 year period beginning 2/8/19, in the form of one share of common stock for each restricted stock unit.
- F2Stock subject to the option will vest 1/4 annually over a 4 year period beginning 2/8/19.